![]() |
Name |
Bipolacochlioquinone B
|
Molecular Formula | C31H46O8 | |
IUPAC Name* |
[2-[16-hydroxy-6-(2-hydroxypropan-2-yl)-3,12-dimethyl-14-oxo-7,11,18-trioxapentacyclo[10.6.1.02,10.03,8.016,19]nonadeca-12,15-dien-15-yl]-4-methylhexan-3-yl]acetate
|
|
SMILES |
CCC(C)C(OC(C)=O)C(C)C1=CC2(O)COC3C2=C(OC2(C)CCC4OC(C(C)(C)O)CCC4(C)C32)C1=O
|
|
InChI |
InChI=1S/C31H46O8/c1-9-16(2)24(37-18(4)32)17(3)19-14-31(35)15-36-26-22(31)25(23(19)33)39-30(8)13-11-21-29(7,27(26)30)12-10-20(38-21)28(5,6)34/h14,16-17,20-21,24,26-27,34-35H,9-13,15H2,1-8H3/t16-,17-,20+,21+,24+,26+,27+,29-,30+,31+/m0/s1
|
|
InChIKey |
KOMDCICQYVDNPI-VIOHRMRVSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 546.7 | ALogp: | 4.0 |
HBD: | 2 | HBA: | 8 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 111.5 | Aromatic Rings: | 5 |
Heavy Atoms: | 39 | QED Weighted: | 0.464 |
Caco-2 Permeability: | -4.97 | MDCK Permeability: | 0.00001520 |
Pgp-inhibitor: | 0.999 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.018 | 20% Bioavailability (F20%): | 0.172 |
30% Bioavailability (F30%): | 0.543 |
Blood-Brain-Barrier Penetration (BBB): | 0.6 | Plasma Protein Binding (PPB): | 89.09% |
Volume Distribution (VD): | 1.895 | Fu: | 6.23% |
CYP1A2-inhibitor: | 0.004 | CYP1A2-substrate: | 0.271 |
CYP2C19-inhibitor: | 0.029 | CYP2C19-substrate: | 0.809 |
CYP2C9-inhibitor: | 0.067 | CYP2C9-substrate: | 0.013 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.052 |
CYP3A4-inhibitor: | 0.736 | CYP3A4-substrate: | 0.823 |
Clearance (CL): | 3.624 | Half-life (T1/2): | 0.043 |
hERG Blockers: | 0.006 | Human Hepatotoxicity (H-HT): | 0.356 |
Drug-inuced Liver Injury (DILI): | 0.817 | AMES Toxicity: | 0.068 |
Rat Oral Acute Toxicity: | 0.976 | Maximum Recommended Daily Dose: | 0.928 |
Skin Sensitization: | 0.076 | Carcinogencity: | 0.037 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.007 |
Respiratory Toxicity: | 0.982 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000943 | ![]() |
0.717 | D0W5LS | ![]() |
0.247 | ||
ENC004570 | ![]() |
0.636 | D0Y7LD | ![]() |
0.237 | ||
ENC004251 | ![]() |
0.585 | D0X7XG | ![]() |
0.236 | ||
ENC004573 | ![]() |
0.578 | D0I2SD | ![]() |
0.236 | ||
ENC001862 | ![]() |
0.561 | D04GJN | ![]() |
0.236 | ||
ENC002674 | ![]() |
0.559 | D0X4RS | ![]() |
0.235 | ||
ENC002182 | ![]() |
0.522 | D02CJX | ![]() |
0.233 | ||
ENC003489 | ![]() |
0.522 | D06AEO | ![]() |
0.231 | ||
ENC004572 | ![]() |
0.522 | D02CNR | ![]() |
0.230 | ||
ENC003638 | ![]() |
0.519 | D0W2EK | ![]() |
0.228 |